Skip to main navigation
  • Careers
  • Contact

Menu

Skip to content
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • SEC Filings
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Estimates
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • ADCs
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • ZTlido™
      • RTX
  • Translational Efficiencies

News Releases

fundamentals sub menu

  • Fundamentals

Sorrento Therapeutics Closes Five-Year Term Loan Financing for Up to $150 Million

Nov 08, 2018

Sorrento Therapeutics Anti-CEA CAR-T Demonstrates Significant Therapeutic Activity With Increased Overall Survival in Pancreatic Cancer Patients With Liver Metastases

Nov 06, 2018

Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Nov 01, 2018

Scilex Announces the Availability of ZTlido™

Oct 01, 2018

Sorrento Therapeutics to Present at the Leerink Partners Roundtable Series 10/3/2018

Sep 27, 2018

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

Sep 19, 2018

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication

Sep 10, 2018

Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)

Sep 02, 2018

1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations

Aug 13, 2018

Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics

Jul 03, 2018

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Email Page
Clinical Trials
clinicaltrials@sorrentotherapeutics.com
Investors
investors@sorrentotherapeutics.com
Business Development
business@sorrentotherapeutics.com
Media Requests
mediarelations@sorrentotherapeutics.com
© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • DMCA
  • Trademarks
  • Linking Policy
  • LinkedIn
MENU
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Analyst Coverage
      • Estimates
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • Quarterly Results
      • Fundamentals
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Investor Contact
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • Antibody Drug Conjugates (ADCs)
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • RTX
      • ZTlido™
  • Translational Efficiencies
  • Careers
  • Contact